A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19
Purpose
The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.
Condition
- SARS-CoV-2 Acute Respiratory Disease
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Age ≥ 18 years - Willing to provide informed consent prior to participation. - Cohort 1 (Arm 1) - Positive test results for SARS-CoV-2 virus by an RT-PCR or Antigen test AND not received any COVID-19 vaccine or participated in any COVID-19 vaccine trial - Cohort 2 (Arm 2) - Received the COVID-19 vaccine
Exclusion Criteria
- Unable or unwilling to provide informed consent - Individuals with known conditions or treatments associated with immune impairment, such as cancer and chemotherapy
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Unvaccinated SARS-CoV-2 positive | Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated |
|
| Vaccinated | Participants who were vaccinated against SARS-CoV-2 |
|
Recruiting Locations
More Details
- NCT ID
- NCT05042193
- Status
- Completed
- Sponsor
- Everly Health
Detailed Description
This virtual clinical study will use a prospective design, to evaluate longevity and seroprevalence of IgG against SARS-CoV-2 in approximately 800 patients as measured by Dried Blood Spots via fingerstick using the Everlywell COVID-19 Antibody Test Home Collection Kit. Participants will be followed up to 9 months at 1, 3, 6 and 9 months after enrollment.